Scarletred

29/05/2026

🔊 “If you think you can handle US business only online from Vienna, you are wrong.”

On Thursday, May 28th, Harald Schnidar, CEO & Founder of SCARLETRED, was a panelist at yesterday’s , at the Austrian Economic Chamber (WKO) in Vienna, focusing on:

🌍️"The US Healthcare Market in Focus: Opportunities and Challenges for Austrian Companies."

Some key insights from the panel:

📌 Long-term commitment: Measurable results take 3 to 5 years. Entering a new market is not a side project; it is a top priority.

📌 Sales over perfection: Don’t over-engineer, start the selling process before the product is “Perfect”.

📌 Physical presence is vital: Deals and trust cannot be built overseas. Being there physically is necessary.

📌 Address logistics: Utilize the ecosystem, prepare for intense competition and check your visa status, logistics and conditions early.

A huge thank you to Christa Bleyleben and Victoria Liedl for your remarkable insights on how to enter, operate and evolve in the US Healthcare Market and to Damita Pressl for moderating our panel on stage. 🎤

Thank you to everyone who made this year's possible! 🌟

27/05/2026

🎗️ May is about 🔊

🔬 Skin cancer is one of the most common cancer groups in modern civilization - and one of the most preventable.

Prevention requires more than sunscreen. It demands verified clinical information, objective documentation, and consistent monitoring over time.

📌 A few facts:

In Europe, 7.3 million people are affected - with incidence projected to rise by 34% by 2040.
In the U.S., 1 in 5 Americans is likely to develop skin cancer by age 70.
In Australia and New Zealand, 2 in 3 are likely to be diagnosed in their lifetime.

🔎 Early detection changes outcomes. That is why Scarletred®Vision enables objective, AI-powered skin lesion documentation, quantification, and longitudinal monitoring.

Emerging research goes even further: A monocentric study at the Hospital of Wiener Neustadt is currently investigating whether iris pigmentation may be a predictor for basal cell carcinoma risk - using Scarletred®Vision, powered by ®AI.

👉 Swipe through our gallery to find out more!

26/05/2026

⏰ Reminder!

🔔 This Thursday, May 28th, CEO & Founder Harald Schnidar will take the stage at in Vienna as a panelist on:

🎙️ "The US Healthcare Market in Focus: Opportunities and Challenges for Austrian Companies."

🕑 14:40–15:20 | Main Stage, Julius Raab Saal, Wirtschaftskammer Österreich

Joining the panel:
🔹 Christa Bleyleben, Managing Partner MassGlobal Partners
🔹 Victoria Liedl, Head of Innovation & Technology, AußenwirtschaftsCenter New York
🎤 moderated by Damita Pressl

🌍 is one of Central Europe's biggest events for international business, bringing together over 3.000 entrepreneurs, export experts, and international speakers at the Austrian Economic Chamber.

If you are attending - don't miss this panel. Harald Schnidar brings years of cross-continental business experience to the stage: 📈 Having built and scaled across two continents and managing transatlantic partnerships.

⚡️ We will see you there! 🚀

20/05/2026

🇳🇱 Day #1 at in Amsterdam - what a start ⚡

We are live in Amsterdam at the 7th Dermatology Drug Development Summit ( ) Europe, and the energy in the room is exactly what we hoped for.

As part of the Opening, Harald Schnidar, CEO & Founder of , took the stage as Expert Speaker and delivered his presentation:

"From Images to Evidence: How Mobile Imaging and ®AI Are Redefining Dermatology Drug Development"

With the most influential leaders from pharma and biotech in the room, the conversations around objective skin imaging, clinical data quality, and the future of dermatology drug development are inspiring and forward-thinking. 💬

The summit still has plenty ahead - if you are here, come find us at our booth and let's talk about how standardized, clinically validated skin imaging can strengthen your clinical trial data📍

19/05/2026

🔊 "Its about being there and strengthening long, trustful relationships."

🇦🇹 🇯🇵 How SCARLETRED Holding GmbH is bridging medical innovation and cultural understanding between Austria and Japan. And why, in science and in business, pictures speak more than words. 📸

🌸 On May 18th, Harald Schnidar, CEO & Founder of SCARLETRED, took the stage at the Cherry Blossom Business & Culture Event 2026 at Vienna AirportCity as keynote speaker at the Opening Panel and .

🎙️ His message was clear: international business is not about deals. It's about trust, presence, and the courage to show up - again and again.

once again brought together remarkable voices:
🇦🇹 Federal Minister of Economy, Energy and Tourism Wolfgang Hattmannsdorfer made clear that Austria and Japan are a perfect match - and outlined Austria's ambition to become a top 10 global economy.

🤝 Long-term partnerships were fostered. The kind of platform stands for. 🌸 We are truly grateful for this inspiring event!

Cherry Blossom 2026 also welcomed:
🔹 Michael Otter, ADVANTAGE AUSTRIA | AUSSENWIRTSCHAFT AUSTRIA
🔹 Alf Netek, Wirtschaftskammer Österreich
🔹 Günther Ofner, Executive Director of Flughafen Wien - Vienna Airport Wien AG
🔹 HE Kiminori Iwama, Japanese Ambassador in Austria
🔹 Mr. Tadashi Murakami, General Director of JETRO - Japan External Trade Organization in Austria
🔹 Rumi Onodera, Technology & Innovation Officer at ADVANTAGE AUSTRIA in Tokyo
🔹 Seiichiro Matsumura, Tokyo University of Agriculture and Technology

12/05/2026

Speaker Alert! 🔔

On May 28th, CEO & Founder Harald Schnidar will take the stage at in Vienna as a panelist on:

🎙️ "The US Healthcare Market in Focus: Opportunities and Challenges for Austrian Companies."

Joining the panel:
🔹 Christa Bleyleben, Managing Partner MassGlobal Partners
🔹 Victoria Liedl, Head of Innovation & Technology, AußenwirtschaftsCenter New York
🎤 moderated by Damita Pressl

🌍 is Central Europe's largest internationalization event, bringing together over 3.000 entrepreneurs, export experts, and international speakers at the Austrian Economic Chamber (WKO).

CEO & Founder Harald Schnidar brings 15+ years of cross-continental business experience to the panel:
📈 Having built and scaled across two continents,
🌐 navigating FDA frameworks, US commercialization, and transatlantic partnerships firsthand.

⚡️We're proud to represent Austrian MedTech innovation at this level - and we look forward to inspiring more companies to take the leap across the Atlantic.🚀

07/05/2026

⏰ Counting down to 7th Dermatology Drug Development Summit Europe!

🌟 is proud to be a long-trusted Main Sponsor and Expertise Partner at this year’s Europe!

🗓️ 19th - 21st May 2026
📍Amsterdam, Netherlands

🎙️ Speaker Alert!

Listen to Harald Schnidar, CEO & Founder of , as an at 7th DDDS Europe - presenting:

🔊 From Images to Evidence: How Mobile Imaging and ®AI Are Redefining Dermatology Drug Development

💡 Visit our booth for a hands-on experience of Scarletred®Vision!

By enabling standardized, objective skin imaging at scale, we are supporting pharma and biotech in making faster, data-driven decisions across all phases of clinical research.

Let’s connect and explore how supports clinical trials with standardized documentation and clinically validated, objective skin data 🧬

🌟 We are looking forward to inspiring conversations!

06/05/2026

🌸 Bridging Innovation Across Borders 🌸

SCARLETRED is honored to return to this year’s Cherry Blossom Event at Vienna Airport City as a 🌟

is an inspiring platform that brings together Austrian and Japanese business communities to exchange ideas and shape the future of international partnerships.

At , innovation thrives at the intersection of science, technology, and global cooperation. That’s why this event resonates strongly with our mission. 🤝

🎙️ Speaker Alert!

Our CEO & Founder, Harald Schnidar, will take the stage as a keynote speaker in the Opening Panel, reflecting on how we can address economic challenges in today’s dynamic business environment.

💡From high-level economic dialogue and startup pitches to cultural exchange and networking, the program reflects how collaboration should look like: multidimensional, inclusive, and impactful.

We look forward to meaningful conversations and strengthening the bridge between Austria 🇦🇹 and Japan 🇯🇵

📍 Vienna Airport City
📅 May 18th, 2026
⏰ 9.00 - 17.30

🔗 Find more information on our website: https://www.scarletred.com/news/scarletred-takes-the-stage-at-cherry-blossom-business-and-culture-event-2026-as-gold-sponsor?utm_source=facebook&utm_medium=organic_social&utm_campaign=cherryblossom2026

28/04/2026

🌸 April is not over yet - and so is Awareness Month 🔊

Over 5% of adults worldwide live with Rosacea. And yet, it’s widely misunderstood, often dismissed as simple redness.

Rosacea is more than redness. It is a complex, multi-dimensional skin-disease, involving:

🔎 erythema
🔎 broken blood vessels
🔎 pustules
🔎 inflammatory lesions
🔎 structural skin changes

🔬One of the biggest challenges in managing today:
Measurement is largely subjective - occasionally leading to inaccurate and prolonged treatment.

Scarletred®Vision is here to help:
💪 Powered by ARORA®AI, Scarletred®Vision goes beyond redness – profiling Rosacea in all its dimensions.

👇Swipe through to learn more about and how AI-driven Profiling is changing the way we understand and manage Rosacea.

🌟 Dermatology deserves objectivity, every skin deserves precision.

🔗 Read more in our publication "Beyond Redness: AI-driven Profiling of Rosacea Severity and Morphological Marker": https://www.scarletred.com/publications/beyond-redness-ai-driven-profiling-of-rosacea-severity-and-morphological-marker?utm_source=facebook&utm_medium=organic_social&utm_campaign=rosaceaawareness

22/04/2026

🔬 Building the future of clinical research in Austria 🔬

had the privilege of joining Medical University of Vienna (MedUni Wien) for the official presentation of its New Clinical Research Hub:

💡The Center for Translational Medicine (CTM) and the Eric Kandel Institute – Center for Precision Medicine (CPM).

Thank you for your warm welcome Markus Zeitlinger, Head of Department of Clinical Pharmacology of MedUni Vienna, and Agnes Bugajska-Schretter!

🤝 This invitation reflects a strong and growing collaboration. Over the past years, we have worked together on impactful research projects:

🌟 From medical device studies on the sensitivity and specificity of SARS-CoV-2 rapid antigen tests
🌟 to a first in human Phase Ib trial, validating safety of subcutaneous recombinant Human Superoxide Dismutase (rhSOD) by integrating Artificial Intelligence.

What’s emerging now at the Medical University of Vienna goes far beyond infrastructure:

📍 A new campus designed to bring research, clinical practice, and education closer together - accelerating the translation from lab to patient and fostering data-driven medicine.

🔬 With dedicated spaces such as the CTM and the CPM and a strong focus on interdisciplinary innovation, this development marks a significant step for Austria’s clinical research landscape.

We are proud to contribute to this momentum and look forward to expanding collaboration opportunities 🤝

🔗 Read more about our collaborative research on our website.

SCARLETRED was invited by MedUni Wien to the presentation of its new clinical research hub: the Center for Translational Medicine (CTM) and the Eric Kandel Institute - Center for Precision Medicine (CPM).